|
Gregory J. Flesher joined AVANIR Pharmaceuticals in 2006 as Senior Director of Commercial Strategy and was responsible for lifecycle and new product planning. While in this role, he also led the commercial integration of Alamo Pharmaceuticals following their acquisition. In November 2006 he became the Executive Director of Business Development and Portfolio Strategy and in August of 2007 he was promoted to Vice President of Business Development. Mr. Flesher’s responsibilities include management of ongoing and new strategic partnerships, in/out-licensing activities, strategic planning, and management of AVANIR’s intellectual property portfolio.
Mr. Flesher has over 14 years of biotechnology and pharmaceutical industry experience and has held positions of increasing responsibility across R&D, Sales, Marketing, and Business Development. Prior to joining Avanir, he was a Sales Director at Intermune Pharmaceuticals with responsibility for trade relations, managed care, and patient support programs. Mr. Flesher also has brand management and commercial analytics experience from Amgen Inc., and Eli Lilly and Company. He began his career within the R&D organization of Eli Lilly and Company.
Mr. Flesher completed his undergraduate studies in Biology at Purdue University, West Lafayette, IN and his doctorate studies in Biochemistry and Molecular Biology at Indiana University School of Medicine, Indianapolis, IN. | 